Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biom...

Full description

Bibliographic Details
Main Authors: Karen E. Mulder, Jennifer L. Spratlin
Format: Article
Language:English
Published: MDPI AG 2011-09-01
Series:International Journal of Molecular Sciences
Subjects:
cDK
Online Access:http://www.mdpi.com/1422-0067/12/9/5895/